NR-546 Week 7 puts two territories in the same paper because they meet constantly in practice: attention disorders treated with controlled agents, and substance use disorders treated with medication. Both turn on the same writing discipline. Define the behaviour you intend to change, measure it with something repeatable, and build safeguards into the plan rather than bolting them on at the end. Your section may print this as NR 546 or NR546; it is the same course.
Chamberlain publishes no syllabi outside Canvas. The placement here is our teaching judgment from the course's catalog arc; your section's rubric decides what your week actually asks.
What NR-546 Week 7 asks for
On the attention side, expect the two stimulant families compared on how they act rather than on brand familiarity, expect the difference between immediate and extended release framed as a coverage question across a person's day, and expect the non stimulant options with their slower onset and their place for patients where a controlled agent is unsuitable. Expect the pre treatment work: a cardiovascular history and family history taken seriously, a baseline of the behaviours you intend to change, and growth measurement where the patient is a child. Expect diversion and misuse handled as a system to design rather than a suspicion to hold.
On the substance use side, expect medications for opioid use disorder taught by mechanism, with the agonist, partial agonist and antagonist approaches producing different treatment structures and different retention profiles. Expect the agents used in alcohol use disorder and the pharmacologic supports for tobacco. Expect the frequent overlap between attention difficulties and substance use, which is where sequencing becomes the interesting clinical question.
Deliverable shapes at this point commonly ask for a plan with monitoring and safeguards, sometimes with a discussion contribution on co-occurring presentations if your section runs one.
The NR-546 Week 7 method, step by step
-
Define the behaviours and the instrument in the same paragraph
Not inattention as a word. Specific behaviours in specific settings, with a rating instrument and informants named. Everything you claim about response depends on this baseline existing.
-
Complete the screen before the prescription
Cardiovascular history, family history, current substance use, sleep, and any other diagnosis that could explain the presentation. Write what you found and what it changed. A screen with no consequence is a formality.
-
Choose the formulation around the day, not the drug
When does the person need coverage, when do they eat, when do they sleep, when do they drive. Duration of action is the deciding variable more often than the molecule is, and saying that shows practical understanding.
-
Design the safeguards into the plan
Prescription monitoring database checks, quantity and refill structure, storage, what happens with a lost prescription, and the frequency of review. Written as routine practice applied to everyone, not as a response to this patient.
-
Sequence the co-occurring problems explicitly
Say which you address first, why, and what would change the order. This is the paragraph where a rubric row about clinical judgment gets answered, and it is the one most often missing.
-
Define what success looks like at the review point
The instrument repeated, the behaviours reassessed, and for substance use treatment, retention and function rather than a single abstinence measure. Name the number or the change you would accept.
Shape of a controlled treatment plan
Our sizing for a paper of roughly 1,250 words. If your week's rubric separates the substance use content into its own row, run the last three rows twice at reduced length.
| Section | What it must document | Word target |
|---|---|---|
| Presentation and baseline | The behaviours, the settings, the informants and the instrument used. | 190 |
| Pre treatment screen | Cardiovascular, substance, sleep and alternative explanations, with findings. | 190 |
| Mechanism and choice | What the chosen agent does, and why it fits this presentation and this day. | 220 |
| The option refused | What you set aside, the deciding factor, and what would bring it back. | 130 |
| Safeguards | Database checks, quantities, storage, refill structure and review frequency. | 200 |
| Co-occurring sequencing | What is treated first, why, and what would change the order. | 170 |
| Review and outcome measures | When, what is repeated, and what result would count as success. | 140 |
Evidence and citation craft in a controlled substance week
Rating instruments are evidence and should be named. A validated scale with informants is citable and repeatable. Clinical impression is neither, and a plan built on it cannot demonstrate response.
Retention is a legitimate outcome and often the right one. In treatment for opioid use disorder, staying in care predicts survival. Citing retention data rather than abstinence rates shows you understand what the evidence measures.
Report effect sizes where your source gives them. A statement that a treatment works is weaker than a statement of how much it moved a rated measure, in whom, over what period.
Regulatory requirements vary by jurisdiction. Where you describe monitoring database use or prescribing rules, say that requirements differ by state and cite the general principle rather than asserting one rule everywhere.
Write about substance use in person first language. A person with a substance use disorder, not a label. This is a graded register matter in psychiatric writing, not a stylistic preference.
Five mistakes that cost points in week 7
- No baseline measurement. Without an instrument and a starting score, no claim about response at the review point can be defended.
- Safeguards written as suspicion. Framing monitoring as a response to this patient's untrustworthiness misreads the practice and the row. It is universal precaution, applied to everyone.
- Formulation chosen with no reference to the person's day. Duration of coverage is the practical question, and ignoring it produces a plan that fails outside the clinic.
- Co-occurring problems named and never sequenced. Listing both and treating neither first leaves the hardest judgment in the case unmade.
- Abstinence used as the only outcome. Function, retention and reduced harm are measurable outcomes with evidence behind them, and a paper that ignores them misrepresents the treatment.
Six checks before this one submits
- A named instrument and a baseline appear before any agent is chosen
- The pre treatment screen lists findings and what each one changed
- Formulation is justified against the person's daily schedule
- Safeguards are described as routine practice with specific components
- The order of treatment for co-occurring problems is stated with a reason
- Outcome measures include function or retention, not abstinence alone
Controlled prescribing week with two territories in one paper?
Send the case and the rubric from Canvas. An original premium plan comes back inside 24 to 48 hours with a measured baseline, safeguards written as routine practice, and the sequencing question answered directly.